文献速递神经免疫

临床发作对水通道蛋白4抗体阳性视神经脊髓炎谱系疾病患者残留残疾的定量贡献

Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
PubMed 文献 · Neurology · 2024-12-12

该回顾性单中心研究纳入165例AQP4抗体阳性NMOSD患者,量化临床复发对残留残疾的贡献。每次复发EDSS平均增加0.304,其中横贯性脊髓炎合并视神经炎表型贡献最大(增加1.290),每次视神经炎发作LogMAR平均增加0.464。复发相关残疾进展因表型和发病年龄而异。

要点

  • 每次复发EDSS平均增加0.304(95%CI 0.074-0.553,P<0.001)。
  • 横贯性脊髓炎合并视神经炎表型每次复发EDSS增加1.290(95%CI 0.233-2.207,P=0.017),贡献最大。
  • 每次视神经炎发作LogMAR平均增加0.464(95%CI 0.199-0.741,P<0.001)。

核心结论

  • 复发对AQP4-NMOSD患者残留残疾的定量贡献因表型而异,复发相关残疾进展也可能因发病年龄而异。
  • 尽管这项回顾性单中心研究可能需要在其他数据集中验证,这些发现可能有助于预测残疾,并为新干预措施的成本效益分析提供长期残疾建模工具。

研究设计与样本

  • 回顾性观察性单中心研究,纳入牛津国家NMO服务中心的165例AQP4-NMOSD患者。
  • 纳入标准为:AQP4-NMOSD诊断,且至少有一次在发作后≥6个月记录的残疾评分(EDSS或LogMAR)。
  • 采用单变量和多变量线性混合效应模型量化临床复发对结局的影响。

主要发现

  • 共纳入165例患者,中位发病年龄43岁(范围2-84);女性140例(84.8%);白人欧洲患者92例(55.8%),非洲或非洲裔英国患者40例(24.2%),亚洲或亚裔英国患者20例(12.1%),多种族或未知种族患者13例(7.9%)。
  • 残疾测量距末次发作的中位时间为32个月(范围6-197)。
  • 每次复发EDSS评分平均增加0.304(95%CI 0.074-0.553,P<0.001)。
  • 横贯性脊髓炎合并视神经炎表型每次复发EDSS增加1.290(95%CI 0.233-2.207,P=0.017);脑部合并其他表型β=0.782(95%CI 0.029-1.03,P<0.001);孤立性横贯性脊髓炎β=0.295(95%CI 0.074-0.549,P<0.001);单纯脑部或单纯视神经复发均与EDSS残留变化无关。
  • 每次视神经炎发作LogMAR评分平均增加0.464(95%CI 0.199-0.741,P<0.001);种族、性别和急性治疗时机对EDSS和LogMAR评分无显著影响。

局限性

  • 原文指出该研究为回顾性单中心研究,可能需要在其他数据集中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Disease-related disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) is solely attributed to clinical attacks. However, few studies have assessed the relationship between attacks and residual disability in NMOSD. Thus, we aimed to quantify the contribution of clinical attacks to the residual disability in patients with AQP4-NMOSD. METHODS: This retrospective observational single-center study enrolled patients from the Oxford National NMO Service, with the inclusion criteria as (1) AQP4-NMOSD diagnosis and (2) availability of at least 1 disability score (Expanded Disability Status Scale [EDSS] or logarithm of the minimum angle of resolution [LogMAR] score) recorded ≥6 months after attack (defined as residual disability). The outcome measures were EDSS and LogMAR scores. Univariable and multivariable linear mixed-effect models were used to quantify the effect of clinical relapses on the outcomes. RESULTS: A total of 165 patients with AQP4-NMOSD (median onset age, 43 years, range 2-84; women, 140 [84.8%]; White European patients, 92 [55.8%]; African or African British patients, 40 [24.2%]; Asian or Asian British patients, 20 [12.1%]; multiracial or unknown racial patients, 13 [7.9%]) were included, with the median time of disability measurement since the last attack being 32 months (range 6-197). The mean increase in the EDSS score per relapse was 0.304 (95% CI 0.074-0.553, p < 0.001), with individual relapse phenotypes showing different effects: the transverse myelitis (TM) + optic neuritis (ON) phenotype contributed most, with an increase of 1.290 (95% CI 0.233-2.207, p = 0.017) per relapse, followed by brain plus other phenotypes (β = 0.782, 95% CI 0.029-1.03, p < 0.001) and isolated TM (β = 0.295, 95% CI 0.074-0.549, p < 0.001), while neither brain nor optic nerve relapse alone was associated with a residual change in the EDSS score. Older onset age was correlated with more severe motor disability where this mainly occurred early in the disease course while younger patients exhibited mild initial disability that worsened more significantly with relapses. Each ON attack led to a mean increase of 0.464 (95% CI 0.199-0.741, p < 0.001) in the LogMAR score. Race, sex, and timing of acute treatment did not significantly affect these disability outcomes (EDSS and LogMAR scores). DISCUSSION: The quantitative contribution of relapse to the residual disability in patients with AQP4-NMOSD varies across phenotypes, and this relapse-related disability progression may also vary by the onset age. Although this retrospective single-center study may need validation in other data sets, these findings may help predict disability and provide a modeling tool for longer term disability in the cost-effective analysis of newer interventions.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Chen B, Francis A, Cooper SA, et al. Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder. Neurology. 2024. PMID: 39666920. doi:10.1212/WNL.0000000000210137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。